新数据显示,在长期治疗亚托皮性皮炎时,阿达西替尼和特拉洛金姆安全,支持在其他健康问题患者中使用. New data show upadacitinib and tralokinumab are safe long-term for atopic dermatitis, supporting use in patients with other health issues.

对于阿托皮性皮炎治疗的乌帕达西提尼布和特拉洛金姆的长期安全性数据显示,没有增加癌症或心脏问题等严重不良事件的风险,支持在患有并发症的患者中使用这些药物. Long-term safety data for upadacitinib and tralokinumab in atopic dermatitis show no increased risk of serious adverse events like cancer or heart problems, supporting their use in patients with comorbidities. 较新的治疗方法,包括尼莫利祖马布,塔皮纳洛夫和罗夫胺乳,提供了更好的安全性和有效性,特别是在儿童和那些需要无类固醇选择的人群中. Newer treatments, including nemolizumab, tapinarof, and roflumilast cream, offer improved safety and efficacy, especially for children and those needing steroid-free options. 专家强调解决皮肤疼痛,共同决策,及时切换治疗,当目标未实现时,强调以患者为中心的护理和更好的沟通,以克服治疗惯性和改善结果的重要性. Experts stress the importance of addressing skin pain, shared decision-making, and timely therapy switches when goals aren’t met, emphasizing patient-centered care and better communication to overcome therapeutic inertia and improve outcomes.